ACR Convergence 2023 Highlights: Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT) | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

ACR Convergence 2023 Highlights: Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

By Highlights from ACR Convergence 2023 FEATURING Kathryn Torok

By Highlights from ACR Convergence 2023 FEATURING Kathryn Torok

109 views

December 20, 2023

The above content is not sponsored by, nor part of, the American College of Rheumatology. ...
read more ↘

Comments 0

Login to view comments. Click here to Login